Clairity Breast, an image-based artificial intelligence platform that can help clinicians predict five-year breast cancer risk based solely on a routine mammogram, is now the first such breast cancer ...

Combining standard adjuvant chemotherapy with the immune checkpoint inhibitor atezolizumab [Tecentriq] leads to a significant improvement in disease-free survival in a subset of patients with Stage ...

A new study by researchers at the American Cancer Society (ACS) shows Medicaid expansion was associated with an increase in Medicaid coverage, early-stage cancer diagnoses, and improved two-year ...

Results from the Phase III SERENA-6 clinical trial found that switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for ...

A pre-surgical combination therapy including pembrolizumab [Keytruda] plus dabrafenib [Tafinlar] and trametinib [Mekinist] (DTP) significantly improved survival in patients with rare BRAF ...

Chemotherapy doesn’t just kill cancer cells. It also affects the microbes in the digestive tract. Researchers at UC San Francisco have discovered that some gut bacteria can reduce the side effects of ...

People who used GLP-1 receptor agonists, like Ozempic, had a modestly lower risk for obesity-related malignancies, especially colon and rectal cancer.

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025 and projected to exceed 22 million by 2035, according to a new report, ...

On May 15, the Food and Drug Administration (FDA) approved Zynyz (retifanlimab) immunotherapy for people with advanced anal cancer based on promising results from a late-stage clinical trial. This ...

The new website CancerSurvivalRates.com has launched with the promise of providing people with cancer and their families a simple way of getting information about the typical survival rates for their ...

Adding inavolisib to palbociclib and fulvestrant improved overall survival for people with previously treated PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer.

Accurate classification of breast cancer receptor status can help guide treatment decisions, making more patients eligible for HER2 targeted therapies.